RxDoctor Payments Data

Richard Cardosi, MD

Gynecologic Oncology · Lakeland, FLNPI 1396717575

Payments from drug & device makers

$4,986in general payments, 2019–2025

Across 150 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Merck$543
  • GSK$339
  • Clovis Oncology, Inc.$335
  • Daiichi Sankyo Inc.$326
  • AstraZeneca$325
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$1,42529%
  • Food & beverage$3,40968%
  • Education$1533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,986 in reported general payments places this provider in the 40th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$708,528
Medicare patients
337
Services billed
17,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$34,229
Megestrol Acetate74$4,810
Enoxaparin Sodium156$3,346
Naloxone Hcl37$2,206
Estradiol25$1,496
Dexamethasone134$623
Tamoxifen Citrate27$588
Oxycodone Hcl89$448
Letrozole28$375
Tolterodine Tartrate ErTolterodine Tartrate13$360
Clobetasol Propionate17$341
Gabapentin32$306
Ondansetron Hcl45$293
Ondansetron OdtOndansetron14$289
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$34,22942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 117 gynecologic oncology providers in Florida.

Other gynecologic oncology in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →